Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FXFTT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CIRCR201-dPBD
|
|||||
| Synonyms |
CIRCR201 dPBD
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
Lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-MET mAb cIRCR201
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Glucuronide-dPBD
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Iso-PEG5-beta-glucuronide
|
Linker Info | ||||
| Conjugate Type |
Glycine linker (G7) and a CaaX motif (Cys-Val-Ile-Met) sequence were inserted into the light-chain C-terminus of the IRCR201 antibody, followed by orthogonal functionalization of Cys 222 site of antibody through prenylation using farnesyltransferase (FTase).
|
|||||
| Combination Type |
A-Glucuronide-dPBD-PEG5-NH2
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.